Intravitreal Aflibercept vs Laser Therapy for Retinopathy of Prematurity: Two-Year Efficacy and Safety Outcomes in the Nonrandomized Controlled Trial FIREFLEYE next

Prospective long-term data after retinopathy of prematurity (ROP) treatment with anti-vascular endothelial growth factor injections vs laser therapy are scarce. The FIREFLEYE (Aflibercept for ROP IVT Injection vs Laser Therapy) next trial is prospectively evaluating the long-term efficacy and safety...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	JAMA network open 2024-04, Vol.7 (4), p.e248383
Hauptverfasser:	Stahl, Andreas, Nakanishi, Hidehiko, Lepore, Domenico, Wu, Wei-Chi, Azuma, Noriyuki, Jacas, Carlos, Vitti, Robert, Athanikar, Aditya, Chu, Karen, Iveli, Pablo, Zhao, Fei, Leal, Sergio, Schlief, Sarah, Schmelter, Thomas, Miller, Thomas, Köfüncü, Evra, Fielder, Alistair
Format:	Artikel
Sprache:	eng
Schlagworte:	Angiogenesis Inhibitors - adverse effects Angiogenesis Inhibitors - therapeutic use Child, Preschool Clinical trials Female Gestational age Humans Infant Infant, Newborn Intravitreal Injections Laser Therapy - adverse effects Laser Therapy - methods Lasers Male Online Only Ophthalmology Original Investigation Prospective Studies Receptors, Vascular Endothelial Growth Factor - therapeutic use Recombinant Fusion Proteins - administration & dosage Recombinant Fusion Proteins - adverse effects Recombinant Fusion Proteins - therapeutic use Retinal detachment Retinopathy of Prematurity - drug therapy Retinopathy of Prematurity - surgery Retinopathy of Prematurity - therapy Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!